Gt biopharma appoints new member to its board of directors

San francisco, california, june 13, 2025 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary trike® natural killer (nk) cell engager platform, today announced the appointment of david c. mun-gavin to its board of directors.
GTBP Ratings Summary
GTBP Quant Ranking